Skip to main content

Table 1 Patient demographics and clinical characteristics.

From: Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus

Patient number Sex Diagnosis Site involvement Reason for inclusión ANA/dsDNAα antibodies Anti-Ro/SSA/La/SSB antibodies CLASI A/D Previous received treatment
1 F DLE (L) V-neck, arm T lack of efficacy, PN 1/640 (123) +/- 6/2 TCS, OCS, HCQ, T
2 F Lupus Profundus Arm, back T lack of efficacy 1/160 (-) -/- 7/1 TCS, OCS, HCQ, T
3 F DLE (L) Arm T lack of efficacy 1/640 (-) -/- 3/1 TCS, OCS, HCQ, T
4 F ACLE Face, v-neck T side effects 1/640 (54) -/- 6/0 TCS, OCS, HCQ, T, AZA,
5 F Lupus Profundus Scalp, face, arms T side effects 1/640 (144) -/- 19/6 TCS, OCS, HCQ, MMF, T
6 F SCLE Face, v-neck, back > 18% body surface 1/640 (-) +/- 19/0 TCS, OCS, MMF
7 F SCLE Face, v-neck, hands, arms T side effects, PN, > 18% body surface 1/640 (83) -/- 20/1 TCS, OCS, HCQ, AZA, T
8 F DLE (L) Face, scalp, ear lobe T side effects 1/40 (-) -/- 9/0 TCS, OCS, HCQ, T
9 F DLE (G) Face, ear lobe, arms, neck > 18% body surface, T side effects 1/320 (37) -/- 13/2 TCS, OCS, HCQ, MMF, T
10 F LET Face T side effects, PN 1/640 (-) -/- 6/0 TCS, HCQ, T
11 F DLE (G) Face, scalp, back T side effects, > 18% body surface 1/40 (-) +/- 15/9 TCS, OCS, HCQ, T
12 F DLE (G) Face, v-neck, back, scalp T side effects, PN 1/40 (-) +/- 17/8 TCS, OCS, HCQ, T
13 F DLE (L) Face T lack of efficacy 1/160 (-) -/- 3/0 TCS, HCQ, T
14 F DLE (G) Face, v-neck T side effects 1/640 (-) -/- 11/2 TCS, OCS, HCQ, MMF, T
15 F DLE (L) Face, scalp T side effects 1/40 (-) -/- 10/3 TCS, OCS, HCQ, T
  1. αNormal value of anti-dsDNA antibodies is < 15 IU/ml. A, activity; ACLE, acute cutaneous lupus erythematosus; ANA, antinuclear antibodies; AZA, azathioprine; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; D, damage; DLE, discoid lupus erythematosus; G, generalized; HCQ, hydroxychloroquine; L, localized; LET, lupus erythematosus tumidus; MMF, mycophenolate mofetil; OCS, oral corticosteroids; PN, polyneuropathy; SCLE, subacute cutaneous lupus erythematosus; T, thalidomide; TCS, topical steroids.